Decent Holding (DXST): H1 Revenue Triples to $18.6M While the Stock Falls Off a Cliff

Decent Holding Inc. (NASDAQ: DXST) reported first-half fiscal 2026 revenue of $18.6 million on August 3. That is up from $5.5 million in the same period a year earlier - a 238% jump that would headline a growth article anywhere else. The stock is at $2.26. It closed 86% below its 200-day moving average of $16.34. The revenue number is not the problem. The factor stack is.

The market has already done its work here. The question is whether anything in the numbers supports a reversal or whether DXST is a company in transition that hasn't earned a valuation yet.

The headline numbers, then the context

Total revenue surged to $18.6 million in the six months ended April 30, 2026, from $5.5 million in H1 FY2025. Gross profit followed to $6.2 million, up from $1.5 million. Gross margin sat at roughly 33%, meaning Decent kept about 33 cents of every dollar as gross earnings before operating costs.

But net loss widened to $1.1 million, up from $480,000 in the prior-year period. Revenue more than tripled and the loss roughly doubled. That tells you operating expenses outpaced the top-line growth by a wide margin.

For comparison, the full fiscal year 2025 (ended October 31, 2025) produced $12.9 million in revenue and a net loss of $322,000. H1 FY2026 alone accounts for $18.6 million of revenue - already 44% above the entire prior fiscal year. The top-line acceleration is real. The question is whether the cost structure can ever bend back.

The old business is shrinking; the new one is unproven

Decent Holding listed on the Nasdaq as a wastewater treatment and river water quality management provider in China. That remains the company's official description in its own filings. But the financials show a business in active transition.

In FY2025, wastewater treatment revenue surged 68.7% to $4.2 million, while the river water quality and product segments declined. Operating expenses exploded 375% to $3.5 million, driven by a $900,000 increase in provisions for credit losses (money set aside for customers who may not pay), higher consulting fees, and R&D spending. The result: a net loss on $12.9 million of revenue, versus net income of $2.1 million in FY2024.

Then in March 2026, management announced a pivot into senior care through a new subsidiary called Suncare (Shanghai) Health Technology. The platform targets China's estimated $4 trillion aging-population market with AI-driven health monitoring, community wellness centers, and chronic disease management. As of July 30, Decent reported over 550 community service centers and more than 180,000 paid members. The July 8 update had cited 480 centers and 150,000 members. So the network added roughly 70 centers and 30,000 members in three weeks.

Here is what the H1 FY2026 filing does not tell us: how much of that $18.6 million came from Suncare versus the legacy wastewater business. The company does not yet break out Suncare as a separate segment. Without that split, we cannot tell whether the revenue explosion is organic wastewater demand, early-stage Suncare monetization, or something in between. That is a data gap that matters, because the margin profile and scalability of those two businesses are completely different.

The factor stack

Valuation. No usable data. The company does not trade at any conventional multiple. With a market cap of roughly $22 million (at $2.26 per share) and annualized revenue that would exceed $35 million if H1 runs the table, the stock trades below 1x sales. That sounds cheap until you factor in the losses, the dual-class share structure (Class B shares carry 20 votes per share), and the absence of analyst coverage or earnings estimates. There is no PE to compare because there are no earnings. There is no forward multiple because nobody is modeling it. In my framework, a stock with no valuation anchor and no earnings path gets treated as speculative, not value.

Growth. A+ on the headline, ungraded on the substance. Revenue tripled. That is the kind of top-line acceleration that puts a company on watchlists. But growth without a margin or profitability counterpoint is incomplete. The $1.1 million loss on $18.6 million of revenue means the business is spending more than it earns to generate that top line. If Suncare revenue is embedded in the number and those 180,000 members are paying recurring fees, the growth quality could be better than the wastewater project business that preceded it. I just don't have the segment data to grade it yet.

Profitability. D−. Gross margin of roughly 33% is decent for a service business. But the net loss rate of 5.8% ($1.1M loss on $18.6M revenue) tells you operating costs - selling, G&A, and the cost of scaling a new platform - are consuming the entire gross profit and then some. In FY2025, the company swung from $2.1 million of net income to a $322,000 loss while revenue grew 12%. The cost structure has been out of whack for two reporting periods. That's a pattern, not a blip.

Safety. D. The company held $838,415 in cash as of April 30, 2025. We don't have a fresh balance sheet for the H1 FY2026 period, but with a $1.1 million loss in six months and a new business line requiring center build-outs, the cash runway is thin. The $600,000 provision for doubtful debts in H1 FY2025 - money set aside for customers who weren't paying - was an early warning sign about receivables quality that the company has not walked back.

Momentum. F. The RSI sits at 48, essentially neutral. The stock is trading at $2.26 versus a 50-day moving average of $2.45 and a 200-day moving average of $16.34. That 200-day number tells you the most: the stock has fallen 86% from its long-term trend. The MACD line is negative. There is zero momentum support. A stock this far below its 200-day MA with no catalyst in sight is not a "deep value" trade - it's a stock the market has already voted on.

What this means for the portfolio

Decent Holding is a company caught between two identities. The wastewater business that brought it to public markets is still described in its official profile, but the financial trajectory - widening losses, surging operating expenses, declining cash - suggests it isn't the engine anymore. The senior care platform that management is building has real scale metrics (550 centers, 180,000 members) but no revenue attribution in the latest filing. The H1 FY2026 results show top-line growth that masks a profitability problem that is getting worse, not better.

There is no portfolio sleeve where DXST fits right now. It is too speculative for a quality-growth allocation, too unproven for a deep-value play, and too small for any income or barbell purpose. The factor stack gives you growth on one axis and red lights on the other four.

If you are watching it, the trigger to reconsider is straightforward: the next filing that breaks out Suncare revenue as a separate segment. If that revenue is material, growing, and carrying better margins than the legacy business, the story changes from "pivot with no proof" to "new growth engine." Until then, the $2.26 price is not a bargain - it's the market assigning zero optionality premium to a company that hasn't yet demonstrated its new model.

The process says wait for the factor stack to confirm the pivot, not bet on it.